# A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma

> **NCT07372287** · PHASE3 · RECRUITING · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 230 (estimated)

## Conditions studied

- Moderate to Severe Asthma

## Interventions

- **DRUG:** CM326
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07372287
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-23
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-03-31
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07372287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07372287, "A Phase III Study of CM326 in Subjects With Moderate to Severe Asthma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07372287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*